Tim Reilly is Vice President and Head of Oncology Early Asset Development at Bristol-Myers Squibb Company in Princeton, New Jersey. In that role, Tim is responsible for establishment of the overall vision, strategic and operational plans and leadership of cross-functional teams overseeing all nonclinical & clinical aspects of BMS’ early oncology portfolio. He has a proven track record of 14 years in pharmaceutical R&D, including leadership for development teams for both small molecules and protein/biological therapeutics across a wide range of disease areas including Oncology, Immunoscience, Genetically-Defined and Metabolic Diseases. Prior to joining BMS, Tim was a research fellow at the National Institutes of Health in Bethesda, Maryland. He obtained his undergraduate degree from the University of Notre Dame, his doctoral training in Pharmaceutical Sciences from Wayne State University, and is a board-certified Diplomate of the American Board of Toxicology. Tim is also co-founder and Chief Scientific Office of a non-profit organization, Spinal Muscular Atrophy Research Team (SMART).